Released · Last reviewed
Tirzepatide cost in 2026: compounded, brand and by provider
Compounded tirzepatide costs more than compounded semaglutide, and the gap is structural: fewer FDA-registered facilities can produce injectable-grade tirzepatide, which lifts the price floor across every legitimate provider.
As of September 4, 2026, compounded tirzepatide runs roughly $199–$297 per month for standard programs, with MEDVi reporting the lowest published self-pay price near $199/month and Mochi at $278/month all-in ($199 medication + $79 required membership). Brand Zepbound lists near $1,086/month, with LillyDirect self-pay vials from $299. All competitor figures are Provider Reported; only prices we capture first-party are labeled Verified.
Why tirzepatide costs more than semaglutide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, a more complex molecule than semaglutide, and fewer FDA-registered outsourcing facilities can produce injectable-grade tirzepatide active ingredient. That supply constraint raises the cost floor across all legitimate 503A and 503B providers, which is why a compounded tirzepatide program almost always costs more than the same provider’s compounded semaglutide. Industry reporting flags sustained maintenance pricing below about $200 per month as a red flag for bait-and-switch pricing or non-legitimate sourcing.
Compounded tirzepatide price by provider
| Provider | Medication | Effective all-in | Membership | Evidence status |
|---|---|---|---|---|
| MEDVi | $199 (starting) | $199 | Sometimes | Verification Pending |
| Eden Health | $249–296 | $249–296 | None (bundled) | Verification Pending |
| Mochi Health | $199 | $278 | $79 (required) | Provider Reported |
| Henry Meds | $297 (m2m) | $297–549 | None | Provider Reported |
Sources: provider pricing pages, Forbes Health, U.S. News, and market reporting captured September 2026. Ledger records CMP-*-TIRZ-*. See our affordability methodology.
Brand tirzepatide: Zepbound and Mounjaro
Brand tirzepatide is sold as Zepbound (approved for chronic weight management and obstructive sleep apnea) and Mounjaro (approved for type 2 diabetes). List price is near $1,086 per month, but Eli Lilly’s LillyDirect self-pay vials start around $299 per month. Medicare does not cover Zepbound for weight loss under the current statutory exclusion, though it covers Mounjaro for type 2 diabetes; commercial coverage of Zepbound for weight loss reaches roughly 30–40 percent of large employer plans, almost always with prior authorization.
Compounded versus brand: the trade-off
Compounded tirzepatide is far cheaper than brand at the pharmacy counter, but it is not FDA-approved and carries none of the SURMOUNT trial evidence that backs Zepbound. After the 2025 tirzepatide shortage resolution, routine compounding of copies is restricted to patient-specific circumstances with a documented clinical difference, the same framework that governs compounded semaglutide. Weigh the price gap against the loss of FDA review and trial-backed evidence, and confirm any program dispenses base tirzepatide through a named, state-licensed pharmacy.
Limitations
Most competitor figures here are Provider Reported or Verification Pending, not first-party Verified, because tier-1 provider sites often render pricing client-side or block automated retrieval. Prices shift with promotions, dose strength, and commitment; always confirm the current published price and total mandatory fees on the provider’s own site before enrolling.
Sources
- Forbes Health — Henry Meds review. forbes.com/health
- Evidence ledger records CMP-*-TIRZ-*, BRAND-ZEP-001. evidence-ledger.csv
- Provider pricing and market reporting captured September 2026.
Sources: FDA — human drug compounding and GLP-1 status; clinical evidence via NEJM. Pricing captured September 2026; see evidence ledger. Last reviewed September 2026.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
How tirzepatide is kept current
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.